Market Overview

UPDATE: Jefferies Reiterates Buy Rating, Lowers PT on Myriad Genetics on New Medicare Code Values

Related MYGN
Myriad Genetics' Crescendo Bioscience Offers New Clinical Data on Vectra(R) DA at ACR
Top Performing Industries For November 12, 2014

In a report published Monday, Jefferies reiterated its Buy rating on Myriad Genetics (NASDAQ: MYGN), but lowered its price target from $33.00 to $31.00.

Jefferies noted, “Noridian, MYGN's designated Medicare contractor, released the highly anticipated new molecular pathology reimbursement codes for CY13. The new codes suggest an 8% decrease and a 14% increase for MYGN's BRACAnalysis and COLARIS tests, respectively, relative to current commercial reimbursement rates. We are trimming our FY14 EPS forecast to $1.60 (from $1.65) on the disclosure. Our PT moves to $31 (from $33) on lower cash flow forecasts.”

Myriad Genetics closed on Friday at $25.46.

Latest Ratings for MYGN

DateFirmActionFromTo
Nov 2014Morgan StanleyInitiates Coverage onUnderperform
Aug 2014Credit SuisseMaintainsNeutral
Jun 2014MacquarieMaintainsNeutral

View More Analyst Ratings for MYGN
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (MYGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters